Adam M. Brufsky

基本信息

浏览量：22

职业迁徙

个人简介

Dr. Brufsky's research interests include novel clinical therapeutics for breast cancer, bone-breast cancer interactions and therapeutics, molecular biology of metastatic breast cancer, and novel management strategies for metastatic breast cancer.

Dr. Brufsky currently directs the Comprehensive Breast Cancer Program of the UPMC Cancer Centers and the University of Pittsburgh. He manages approximately 30 clinical trials investigating various aspects of breast cancer etiology and treatment. His main clinical interests are in breast cancer medical oncology with a particular interest in metastatic breast cancer.

研究兴趣

论文共 921 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Abstract PO4-02-03: Distribution of MammaPrint, BluePrint, and Response Predictive Subtypes based on ImPrint and Reprint in ER+/HER2- Invasive Lobular Carcinoma – A FLEX sub study

Rita Mukhtar,Christina Yau,Denise Wolf,Adam Brufsky,Hannah Linden,Natasha Hunter,Reshma Mahtani,Abirami Sivapiragasam,Trevor Feinstein, Fengting Yan,Ian Grady,Priscilla McAuliffe,Michaela Tsai,Joyce O'Shaughnessy,Blanche Mavromatis, Sasha Davis,Josien Haan,William Audeh,Lavanya Samraj

Cancer Researchno. 9_Supplement (2024): PO4-02

引用0浏览0引用

Breast Cancer Screening Interval: Effect on Rate of Late-Stage Disease at Diagnosis and Overall Survival

Margarita L Zuley,Andriy I Bandos,Stephen W Duffy,Durwin Logue,Rohit Bhargava, Priscilla F McAuliffe,Adam M Brufsky,Robert M Nishikawa

Journal of clinical oncology official journal of the American Society of Clinical Oncologyno. 32 (2024): 3837-3846

引用0浏览0WOS引用

Organizational Breast Cancer Data Mart: A Solution for Assessing Outcomes of Imaging and Treatment

Margarita L. Zuley,Jonathan Silverstein,Durwin Logue,Richard S. Morgan,Rohit Bhargava,Priscilla F. McAuliffe,Adam M. Brufsky,Andriy I. Bandos,Robert M. Nishikawa

JCO CLINICAL CANCER INFORMATICS (2024)

引用0浏览0WOS引用

Abstract GS03-07: Protocol-defined Biomarker Analysis in the PALLAS (AFT-05) Adjuvant Trial: Genomic Subtype Derived from RNA Sequencing of HR+/HER2- Early Breast Cancer

Cancer Researchno. 9_Supplement (2024): GS03-07

引用0浏览0引用

EE417 Healthcare Resource Use and Costs of Care in HR+/HER2- Metastatic Breast Cancer: A Retrospective US Claims Data Study

S Collin,J Tse, NF Shaikh,A Near,E Hamilton,A Brufsky,W Gradishar, S Mehta, GH Long, N Toms

Value in Healthno. 6 (2024): S134

引用0浏览0引用

392P Quality-adjusted Time Without Symptoms of Disease Progression or Toxicity of Treatment (Q-Twist) Analysis to Assess Benefit-Risk of Sacituzumab Govitecan (SG) in Previously Treated Patients (pts) with Metastatic Triple-Negative Breast Cancer (Mtnbc)

A.M. Brufsky, A. Bardia,M.S. Sedrak, S. Loibl, S.M. Tolaney,K. Punie, S.A. Hurvitz, K. Kalinsky, J. Cortés, J. O'Shaughnessy,V.C. Dieras, M. Piccart, A. Dasgupta, A.G. Kaushik, C. Lai, L. Shi, H.S. Rugo

Annals of Oncology (2024)

引用0浏览0引用

Effects of Aerobic Exercise on Neurocognitive Function in Postmenopausal Women Receiving Endocrine Therapy for Breast Cancer: the Exercise Program in Cancer and Cognition Randomized Controlled Trial